SEPRANOLONE, CONTROL AND COMPULSION
Peter Nordkild, CEO Asarina Pharma
SEPRANOLONE: A new approach
A US patent has now been granted for Sepranolone for the treatment of OCD (Obsessive Compulsive Disorder), following the release of the new preclinical data in March 2021.
SEPRANOLONE AND SSRIs
As a highly targeted neurosteroid, Sepranolone has no off-target side effects on the Central Nervous System. It has already demonstrated an exceptionally strong safety profile: To date 330 women have taken Sepranolone, for 3 months, with no other side effects than mild and reversible local skin irritation.
“Pharmacological aid could help people who do not experience improvement with CBT reduce stress, improve control and get better results. And because it is so targeted, it may be a strong adjunctive therapy to SSRIs – the other side of the coin if you will, helping treat and reduce compulsive symptoms, as SSRIs help alleviate anxiety and obsessions.” Peter Nordkild, CEO Asarina Pharma
The key to compulsion: seizing the potential
“86% of patients with Tourette have at least one additional disorder – many with OCD, ADHD and more.
“Neurosteroids clearly play a key role in these conditions – yet today there are no neurosteroid-based medications.
“We aim to change that. Let’s not forget – 30 years ago, few people had heard of Serotonin. Now we know it is implicated not just in depression but mood, anxiety, sleep disorders and more.